STERIS to Host Conference Call for FY 2026 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2026
0mins
Should l Buy STE?
Source: Newsfilter
- Conference Call Announcement: STERIS plc will host a conference call on May 12, 2026, at 9:00 a.m. ET to discuss its fiscal 2026 fourth quarter and full year results, demonstrating the company's commitment to transparency and investor communication.
- Earnings Release Timing: The company will issue its financial results after the U.S. market closes on May 11, 2026, ensuring that investors receive the latest financial information prior to the call, thereby enhancing market focus on its performance.
- Replay Service Availability: For investors unable to listen live, STERIS offers a replay of the conference call starting at 12:00 p.m. ET on May 12, 2026, which enhances interaction and information flow between the company and its investors.
- Global Business Context: As a leading global provider of infection prevention products and services, STERIS's conference call not only showcases its leadership in the healthcare sector but also reflects its attention to future market trends and strategic responses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STE
About STE
STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device research and manufacturing facilities, in particular those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
STERIS Announces Quarterly Dividend Distribution
- Quarterly Dividend Announcement: STERIS plc has declared a quarterly dividend of $0.63 per share, payable on June 26, 2026, which aims to enhance shareholder returns and attract more investor interest.
- Record Date for Shareholders: The record date for the dividend payment is set for June 8, 2026, ensuring that shareholders holding stock by this date will receive the dividend, reflecting the company's commitment to shareholder interests.
- Transparent Tax Information: The company provides additional information regarding the U.S. tax treatment of dividends, including required Form 8937, aimed at improving shareholders' understanding of tax compliance and enhancing corporate transparency.
- Industry Leadership Position: As a leading global provider of infection prevention products and services, STERIS's dividend distribution strategy not only reflects its robust financial health but may also further solidify its leadership position in the healthcare industry.
See More
Profitable Companies May Not Last
- Inter Parfums Performance: Inter Parfums (NASDAQ:IPAR) has a trailing 12-month GAAP operating margin of 18.2%, but its modest revenue base of $1.49 billion limits fixed cost leverage, with demand expected to remain flat over the next 12 months, indicating growth challenges ahead.
- STERIS Investment Risks: STERIS (NYSE:STE) shows a trailing 12-month GAAP operating margin of 17.2%, yet its 5% return on invested capital highlights management's difficulties in identifying attractive investment opportunities, while its current share price of $223.44 reflects a forward P/E of 20.7, suggesting potential overvaluation risks.
- Northern Oil and Gas Growth Potential: Northern Oil and Gas (NYSE:NOG) has achieved an exceptional 28.9% annual revenue growth over the past decade, boasting a best-in-class gross margin of 81.1%, with its current stock price of $26.51 indicating a forward P/E of 7.8, showcasing strong cash flow and investment flexibility.
- Market Dynamics Shift: The current market is rapidly distinguishing quality stocks from overvalued ones, with an AI system successfully identifying several potential winners, prompting investors to pay close attention to these shifts to seize investment opportunities.
See More
STERIS to Host Conference Call for FY 2026 Results
- Conference Call Announcement: STERIS plc will host a conference call on May 12, 2026, at 9:00 a.m. ET to discuss its fiscal 2026 fourth quarter and full year results, demonstrating the company's commitment to transparency and investor communication.
- Earnings Release Timing: The company will issue its financial results after the U.S. market closes on May 11, 2026, ensuring that investors receive the latest financial information prior to the call, thereby enhancing market focus on its performance.
- Replay Service Availability: For investors unable to listen live, STERIS offers a replay of the conference call starting at 12:00 p.m. ET on May 12, 2026, which enhances interaction and information flow between the company and its investors.
- Global Business Context: As a leading global provider of infection prevention products and services, STERIS's conference call not only showcases its leadership in the healthcare sector but also reflects its attention to future market trends and strategic responses.
See More
Beta Bionics Shares Surge 10.3% Amid Optimism for Q1 Results
- Stock Performance: Beta Bionics, Inc. (BBNX) rallied 10.3% in the last trading session to close at $13.02, with notable trading volume exceeding typical levels, indicating strong investor interest and reflecting optimism about the company's future performance.
- Financial Expectations: The company is set to release its Q1 2026 financial results, with an anticipated loss of $0.53 per share, representing a year-over-year decline of 1.9%, while revenues are expected to reach $27.75 million, up 57.3% from the previous year, showcasing robust sales growth potential.
- Sales Channel Growth: In the previous quarter, Beta Bionics reported a 57% year-over-year revenue increase, driven by a staggering 295% surge in net sales from the Pharmacy Benefit Plan (PBP) channel, indicating rapidly rising market demand in the medical devices sector.
- Market Attention: Although the EPS estimates for BBNX have remained unchanged over the past 30 days, investors should monitor future earnings estimate revisions closely, as these are closely correlated with short-term stock price movements; the current Zacks Rank is 3 (Hold), reflecting a cautious market outlook on its future performance.
See More
Teleflex Board Updates and Share Repurchase Plan Announced
- Board Member Changes: Teleflex has nominated medical technology veteran Michael J. Tokich as an independent director, expected to be elected at the 2026 Annual Meeting, bringing over 30 years of leadership experience in the medical technology sector to provide strategic guidance and support long-term value creation.
- New Chairman Appointment: Andrew A. Krakauer has been appointed as Chairman of the Board, succeeding Stephen Klasko, who is stepping down; Krakauer has served as a director since 2018 and previously held the CEO position at Cantel Medical Corp., bringing valuable industry experience to drive the company's strategic execution.
- Formation of Growth and Operating Committee: The Board plans to establish a new Growth and Operating Committee aimed at supporting management in operational execution during significant transformations, identifying growth opportunities, and enhancing accountability across the organization to achieve overall strategic objectives.
- Early Share Repurchase Initiation: Teleflex plans to commence share repurchases in the second quarter ahead of schedule, following the anticipated completion of sales of its OEM, Acute Care, and Interventional Urology businesses in the second half of 2026, with the strategy aimed at enhancing shareholder value based on market conditions and cash flow needs.
See More
S&P 500 Stock Analysis and Investment Recommendations
- STERIS Investment Risks: With a market cap of $21.45 billion, STERIS plays a critical role in infection prevention, yet its return on invested capital is only 5%, indicating management struggles to identify attractive investment opportunities; trading at $218.71 per share with a forward P/E of 20.2x suggests limited growth potential.
- Equifax Performance Decline: Equifax, valued at $22 billion, holds detailed financial records on over 800 million consumers, but its adjusted operating margin has decreased by 4.1 percentage points over the past five years, with earnings per share growing only 2.2% annually, and its current share price of $182.39 reflects a forward P/E of 21.1x, indicating competitive weaknesses.
- First Solar Growth Potential: First Solar, with a market cap of $20.96 billion, has achieved an impressive annual revenue growth of 25.4% over the last two years, indicating an expanding market share; its positive free cash flow margin shows the company is at a pivotal point, and its stock price of $195.60 implies a favorable forward P/E of 11.1x, suggesting strong investment value.
- Recommended Market-Leading Stocks: In the current market environment, selecting high-quality stocks is crucial, and StockStory's recommended stocks not only have performed well in the past but also demonstrate ongoing revenue growth and capital return capabilities, making them potential market winners worth investors' attention.
See More
STERIS Announces Quarterly Dividend Distribution
- Quarterly Dividend Announcement: STERIS plc has declared a quarterly dividend of $0.63 per share, payable on June 26, 2026, which aims to enhance shareholder returns and attract more investor interest.
- Record Date for Shareholders: The record date for the dividend payment is set for June 8, 2026, ensuring that shareholders holding stock by this date will receive the dividend, reflecting the company's commitment to shareholder interests.
- Transparent Tax Information: The company provides additional information regarding the U.S. tax treatment of dividends, including required Form 8937, aimed at improving shareholders' understanding of tax compliance and enhancing corporate transparency.
- Industry Leadership Position: As a leading global provider of infection prevention products and services, STERIS's dividend distribution strategy not only reflects its robust financial health but may also further solidify its leadership position in the healthcare industry.
See More
Profitable Companies May Not Last
- Inter Parfums Performance: Inter Parfums (NASDAQ:IPAR) has a trailing 12-month GAAP operating margin of 18.2%, but its modest revenue base of $1.49 billion limits fixed cost leverage, with demand expected to remain flat over the next 12 months, indicating growth challenges ahead.
- STERIS Investment Risks: STERIS (NYSE:STE) shows a trailing 12-month GAAP operating margin of 17.2%, yet its 5% return on invested capital highlights management's difficulties in identifying attractive investment opportunities, while its current share price of $223.44 reflects a forward P/E of 20.7, suggesting potential overvaluation risks.
- Northern Oil and Gas Growth Potential: Northern Oil and Gas (NYSE:NOG) has achieved an exceptional 28.9% annual revenue growth over the past decade, boasting a best-in-class gross margin of 81.1%, with its current stock price of $26.51 indicating a forward P/E of 7.8, showcasing strong cash flow and investment flexibility.
- Market Dynamics Shift: The current market is rapidly distinguishing quality stocks from overvalued ones, with an AI system successfully identifying several potential winners, prompting investors to pay close attention to these shifts to seize investment opportunities.
See More
STERIS to Host Conference Call for FY 2026 Results
- Conference Call Announcement: STERIS plc will host a conference call on May 12, 2026, at 9:00 a.m. ET to discuss its fiscal 2026 fourth quarter and full year results, demonstrating the company's commitment to transparency and investor communication.
- Earnings Release Timing: The company will issue its financial results after the U.S. market closes on May 11, 2026, ensuring that investors receive the latest financial information prior to the call, thereby enhancing market focus on its performance.
- Replay Service Availability: For investors unable to listen live, STERIS offers a replay of the conference call starting at 12:00 p.m. ET on May 12, 2026, which enhances interaction and information flow between the company and its investors.
- Global Business Context: As a leading global provider of infection prevention products and services, STERIS's conference call not only showcases its leadership in the healthcare sector but also reflects its attention to future market trends and strategic responses.
See More
Beta Bionics Shares Surge 10.3% Amid Optimism for Q1 Results
- Stock Performance: Beta Bionics, Inc. (BBNX) rallied 10.3% in the last trading session to close at $13.02, with notable trading volume exceeding typical levels, indicating strong investor interest and reflecting optimism about the company's future performance.
- Financial Expectations: The company is set to release its Q1 2026 financial results, with an anticipated loss of $0.53 per share, representing a year-over-year decline of 1.9%, while revenues are expected to reach $27.75 million, up 57.3% from the previous year, showcasing robust sales growth potential.
- Sales Channel Growth: In the previous quarter, Beta Bionics reported a 57% year-over-year revenue increase, driven by a staggering 295% surge in net sales from the Pharmacy Benefit Plan (PBP) channel, indicating rapidly rising market demand in the medical devices sector.
- Market Attention: Although the EPS estimates for BBNX have remained unchanged over the past 30 days, investors should monitor future earnings estimate revisions closely, as these are closely correlated with short-term stock price movements; the current Zacks Rank is 3 (Hold), reflecting a cautious market outlook on its future performance.
See More
Teleflex Board Updates and Share Repurchase Plan Announced
- Board Member Changes: Teleflex has nominated medical technology veteran Michael J. Tokich as an independent director, expected to be elected at the 2026 Annual Meeting, bringing over 30 years of leadership experience in the medical technology sector to provide strategic guidance and support long-term value creation.
- New Chairman Appointment: Andrew A. Krakauer has been appointed as Chairman of the Board, succeeding Stephen Klasko, who is stepping down; Krakauer has served as a director since 2018 and previously held the CEO position at Cantel Medical Corp., bringing valuable industry experience to drive the company's strategic execution.
- Formation of Growth and Operating Committee: The Board plans to establish a new Growth and Operating Committee aimed at supporting management in operational execution during significant transformations, identifying growth opportunities, and enhancing accountability across the organization to achieve overall strategic objectives.
- Early Share Repurchase Initiation: Teleflex plans to commence share repurchases in the second quarter ahead of schedule, following the anticipated completion of sales of its OEM, Acute Care, and Interventional Urology businesses in the second half of 2026, with the strategy aimed at enhancing shareholder value based on market conditions and cash flow needs.
See More
S&P 500 Stock Analysis and Investment Recommendations
- STERIS Investment Risks: With a market cap of $21.45 billion, STERIS plays a critical role in infection prevention, yet its return on invested capital is only 5%, indicating management struggles to identify attractive investment opportunities; trading at $218.71 per share with a forward P/E of 20.2x suggests limited growth potential.
- Equifax Performance Decline: Equifax, valued at $22 billion, holds detailed financial records on over 800 million consumers, but its adjusted operating margin has decreased by 4.1 percentage points over the past five years, with earnings per share growing only 2.2% annually, and its current share price of $182.39 reflects a forward P/E of 21.1x, indicating competitive weaknesses.
- First Solar Growth Potential: First Solar, with a market cap of $20.96 billion, has achieved an impressive annual revenue growth of 25.4% over the last two years, indicating an expanding market share; its positive free cash flow margin shows the company is at a pivotal point, and its stock price of $195.60 implies a favorable forward P/E of 11.1x, suggesting strong investment value.
- Recommended Market-Leading Stocks: In the current market environment, selecting high-quality stocks is crucial, and StockStory's recommended stocks not only have performed well in the past but also demonstrate ongoing revenue growth and capital return capabilities, making them potential market winners worth investors' attention.
See More
